title: Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
abstract: In the present study we investigated the effects of co-administration of GM(1) (15.0 mg/kg, twice daily, for 30 days) and haloperidol (1.0 mg/kg, twice daily, for 30 days), as well as the effects of a 5-day treatment with this dose of GM(1) after withdrawal from haloperidol in rats. The animals were evaluated in the open-field test and apomorphine-induced stereotyped behaviour. The results show that GM(1) was able to attenuate dopaminergic supersensitivity evaluated by the locomotion frequency at 24 and 48 h after the withdrawal from haloperidol. On the other hand, rearing frequency was changed neither by haloperidol nor by GM(1.) In haloperidol-treated rats immobility time differs from 30 min observation session in comparison with the following sessions after the withdrawal from neuroleptic. Apomorphine-induced stereotyped behaviour produced a significant increase in scores of haloperidol-withdrawn rats. GM(1) did not modify the haloperidol effects and did not change the dopamine receptor affinity to apomorphine 100 h from abrupt neuroleptic withdrawal.
authors.affiliation: Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil.
authors.forename: J C
authors.initials: JC
authors.lastname: Perry
authors.forename: M A B F
authors.initials: MA
authors.lastname: Vital
authors.forename: R
authors.initials: R
authors.lastname: Frussa-Filho
authors.forename: S
authors.initials: S
authors.lastname: Tufik
authors.forename: J
authors.initials: J
authors.lastname: Palermo-Neto
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005677:G(M1) Ganglioside / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology* / Q000627:therapeutic use; D007103:Immobilization; D008124:Locomotion / Q000187:drug effects; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013239:Stereotyped Behavior / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control; D013997:Time Factors
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D005677:G(M1) Ganglioside; D006220:Haloperidol; D001058:Apomorphine